Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 291


Prognosis of preoperative positron emission tomography uptake in hepatectomy patients.

Kim JM, Kwon CHD, Joh JW, Sinn DH, Choi GS, Paik SW.

Ann Surg Treat Res. 2018 Apr;94(4):183-189. doi: 10.4174/astr.2018.94.4.183. Epub 2018 Mar 26.


Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?

Kim KM, Kim J, Sinn DH, Kim HS, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.

Scand J Gastroenterol. 2018 Apr 3:1-7. doi: 10.1080/00365521.2018.1458895. [Epub ahead of print]


Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma.

Yu JI, Yoo GS, Cho S, Jung SH, Han Y, Park S, Lee B, Kang W, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC.

Radiat Oncol J. 2018 Mar;36(1):25-34. doi: 10.3857/roj.2017.00409. Epub 2018 Mar 29.


Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study.

Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, Huh W, Paik SW, Ryu S, Chang Y, Shafi T, Lazo M, Guallar E, Cho J, Gwak GY.

Sci Rep. 2018 Mar 16;8(1):4718. doi: 10.1038/s41598-018-23014-0.


Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy.

Bae J, Sinn DH, Kang W, Gwak GY, Choi MS, Paik YH, Lee JH, Koh KC, Paik SW.

Liver Int. 2018 Mar 1. doi: 10.1111/liv.13732. [Epub ahead of print]


Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization.

Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS.

Dig Dis Sci. 2018 Apr;63(4):1062-1071. doi: 10.1007/s10620-018-4934-6. Epub 2018 Feb 13.


Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.

Kim AY, Sinn DH, Jeong WK, Kim YK, Kang TW, Ha SY, Park CK, Choi GS, Kim JM, Kwon CHD, Joh JW, Kim MJ, Sohn I, Jung SH, Paik SW, Lee WJ.

J Hepatol. 2018 Jun;68(6):1144-1152. doi: 10.1016/j.jhep.2018.01.024. Epub 2018 Mar 5.


Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.

Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ.

N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417.


Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.

Chang Y, Choe WH, Sinn DH, Lee JH, Ahn SH, Lee H, Shim JJ, Jun DW, Park SY, Nam JY, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Kwon SY, Paik SW, Yoon JH.

J Infect Dis. 2017 Dec 12;216(11):1407-1414. doi: 10.1093/infdis/jix506.


Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.

Oh IS, Sinn DH, Kang TW, Lee MW, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.

Dig Dis Sci. 2017 Nov;62(11):3235-3242. doi: 10.1007/s10620-017-4775-8. Epub 2017 Oct 5.


Clinical importance of TERT overexpression in hepatocellular carcinoma treated with curative surgical resection in HBV endemic area.

Yu JI, Choi C, Ha SY, Park CK, Kang SY, Joh JW, Paik SW, Kim S, Kim M, Jung SH, Park HC.

Sci Rep. 2017 Sep 25;7(1):12258. doi: 10.1038/s41598-017-12469-2.


Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.

Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ.

Clin Mol Hepatol. 2017 Dec;23(4):331-339. doi: 10.3350/cmh.2016.0040. Epub 2017 Sep 26.


Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial.

Yu JI, Park HC, Jung SH, Choi C, Shin SW, Cho SK, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Sahinbas H, Paik SW.

Oncotarget. 2017 Apr 13;8(32):52651-52664. doi: 10.18632/oncotarget.17072. eCollection 2017 Aug 8.


Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study.

Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, Ryu S, Chang Y, Lazo M, Guallar E, Cho J, Gwak GY.

J Hepatol. 2017 Dec;67(6):1274-1280. doi: 10.1016/j.jhep.2017.08.024. Epub 2017 Sep 20.


Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma.

Sinn DH, Min YW, Son HJ, Rhee PL, Paik SW, Hong SN, Gwak GY.

PLoS One. 2017 Jun 21;12(6):e0179480. doi: 10.1371/journal.pone.0179480. eCollection 2017.


Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.

Paik N, Sinn DH, Lee JH, Oh IS, Kim JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.

Liver Int. 2018 Jan;38(1):68-75. doi: 10.1111/liv.13489. Epub 2017 Jul 3.


[The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population].

Ko YS, Bae JH, Sinn DH, Gwak GY, Kang W, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.

Korean J Gastroenterol. 2017 Apr 25;69(4):232-238. doi: 10.4166/kjg.2017.69.4.232. Korean.


Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis.

Kim JH, Lim KS, Min YW, Lee H, Min BH, Rhee PL, Kim JJ, Koh KC, Paik SW.

J Gastroenterol Hepatol. 2017 May;32(5):1064-1070. doi: 10.1111/jgh.13637.


Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.

Kao JH, Yu ML, Peng CY, Heo J, Chu CJ, Chang TT, Lee YJ, Hu TH, Yoon KT, Paik SW, Lim YS, Ahn SH, Isakov V, McPhee F, Hu W, Scott Swenson E, Yin PD, Treitel M.

J Gastroenterol Hepatol. 2017 Dec;32(12):1998-2005. doi: 10.1111/jgh.13796.


The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE.

Kim JH, Sinn DH, Shin SW, Cho SK, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS.

Clin Mol Hepatol. 2017 Mar;23(1):42-50. doi: 10.3350/cmh.2016.0058. Epub 2017 Mar 7.

Supplemental Content

Support Center